Market Cap 1.57B
Revenue (ttm) 407.32M
Net Income (ttm) -61.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.12%
Debt to Equity Ratio 1.37
Volume 2,878,700
Avg Vol 3,741,616
Day's Range N/A - N/A
Shares Out 247.03M
Stochastic %K 70%
Beta 0.58
Analysts Strong Sell
Price Target $16.30

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
Noisy
Noisy Jun. 25 at 12:07 AM
$UNCY would be a good buyout target for $ARDX as a lower premium cost drug.
5 · Reply
ToadTrader
ToadTrader Jun. 24 at 6:23 PM
$ARDX Yep..... up to the "head bumping zone" ($6.35 to 6.44) then drop on down, retesting the area of test the 50% line of Monday's 24-hr range! Sideway Dancing..... on the 15-min chart I can see how the price checked back with the 200 SMA dipping down to the $5.75 level, the progressed up into the current working zone. Running now, in the same zone as we did back the last two weeks of May! As I study it all, you can seen then, that in Mid April we reached up to this same level, then tested back into the "BOX" ($5.65 Dip) then up to test higher ($7.47).... before then dipping through the BOX (lower side! $5.31) . This whole three month process is know as a RANGE EXPANSION, typically, an indication of accumulation by someone, be it Bears or Bulls....LOL Waiting it see the long term pattern.... working the daily runs to my preferred direction... study the progress in price to identify the the next wave.... catch the rising tides and avoid the undertows! Stay safe! CHEERS!
0 · Reply
opportoni
opportoni Jun. 24 at 6:19 PM
$ARDX Why all the complaining? After Q1 there were so many posts that this would bleed now with the long 3 months before we get q2 earnings and that we would reach $5 or worse by then. No catalysts and all that. Turns out, the SP holds up quite well. Even the warrant exercises with selling plans that caused drops in the past didn’t hurt. Neither did the proxy approvals. All is good. Time is on our side as it has (almost) always been with this one.
3 · Reply
VegasBlues
VegasBlues Jun. 24 at 6:12 PM
$ARDX $AQST All things considered… good day so far. 🍏🍻 One day hopefully 🤜🤛
0 · Reply
findingthestock
findingthestock Jun. 24 at 5:57 PM
$ARDX The stock price will not go anywhere until this CMS legal issue is resolved. It’s possible Q2 earning may happen before and will be better than Q1 how much better who knows and what will analysts think and the expenses Right now you can make more of a return with Wendy’s stock
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 24 at 5:34 PM
$ARDX v $AUPH valuation & revenue multiples. This is not investment advice & we're not here to bash AUPH. Lupkynis is an amazing drug & Tang just acquired 10% of AUPH. Our mere objective is to document the disconnect between ARDX's potential valuation assuming analyst revenue estimates are credible. ARDX product sales generated 97% gross margins in FY25 v 88% for AUPH. Analysts project ARDX to outsell AUPH by a factor of almost 2.5X over the next 5 years yet ARDX trades at a meaningfully lower valuation (even considering AUPH's $400MM net cash/debt). The attachment compares ARDX's valuation & related multiples v AUPH. We suspect eventually ARDX's BOD will do something so shareholder value is maximized (again assuming analyst revenue estimates are credible). $XBI $IBB $NBI
6 · Reply
Cap_00
Cap_00 Jun. 24 at 5:32 PM
$ARDX one of the least expensive commercial bios out there. Profitablity just around the corner. 1B by 2029 is achieved, Net revenue will be ~400m. Trading at 1.5B valuation. Peak sale for both I & X is around ~1.5-2B... patent to 2041. And they have a next gen NHE3 inhibitor that will announce IND by end of the year. Top notch CEO to boot. I think the lowest price target in in the $13 s. M&A chatter in the recent past. Stock has been getting bids lately. Perhaps, finally it's going break out from this long consolidation.
0 · Reply
Stocks2Retire
Stocks2Retire Jun. 24 at 5:03 PM
$ARDX finally money start flowing into biotechs- except this one, can they stop the cms nonsense and move forward once and for all!
0 · Reply
jbh973
jbh973 Jun. 24 at 4:27 PM
Many people here every day angrily ask why their particular ticker is down. Is it because of world economics? No. Perhaps a short attack? No. Could it possibly be do to a change in interest rates? Again, no. The simple & honest truth of it is that I most likely bought it. When u tick off God as many times as I have here & also in the afterlife, it's His easiest way to zap me. Perhaps I shouldn't of asked Him after my 2nd heart attack if all those fellas playing harps use pronouns he wouldn't of sent me back so quickly. Oh well. The never ending battle continues with THE MIDDAY STOCK MARKET REVIEW ( The I'm in no particular hurry so Heaven can wait Edition ) $NGEN Added more just because I'm a stubborn cuss. $CPB Pretty sure I single handedly knocked them off the S&P 500 but continue to add soup to my bowl. $LKNCY Adding despite China banning me from stepping foot on their soil. $ARDX Maybe something to do with Aardvarks? added more anyway. $NLY Raised divy. adding more with caution.
1 · Reply
VectorCapitall
VectorCapitall Jun. 24 at 3:45 PM
$ARDX continues to draw attention as investors focus on improving profitability and strong product growth. The company is approaching an earnings inflection point, while forward expectations continue to improve. Even under more conservative assumptions, the valuation remains compelling relative to future potential. The early August earnings report will be the next major catalyst.
0 · Reply
Latest News on ARDX
Ardelyx assumed with a Buy at Ladenburg

2026-06-16T11:57:58.000Z - 8 days ago

Ardelyx assumed with a Buy at Ladenburg


Ardelyx Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Ardelyx Proxy statement: Proxy filing


Ardelyx Proxy statement: Proxy filing

May 19, 2026, 8:00 AM EDT - 5 weeks ago

Ardelyx Proxy statement: Proxy filing


Ardelyx reports Q1 EPS (15c), consensus (14c)

2026-04-30T21:07:15.000Z - 7 weeks ago

Ardelyx reports Q1 EPS (15c), consensus (14c)


Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 7 weeks ago

Ardelyx Earnings Call Transcript: Q1 2026


Ardelyx Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 7 weeks ago

Ardelyx Earnings release: Q1 2026


Ardelyx Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 7 weeks ago

Ardelyx Quarterly report: Q1 2026


Ardelyx Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Proxy statement: Proxy filing


Ardelyx appoints Ettenberg as Chief Legal Officer

2026-04-20T12:50:41.000Z - 2 months ago

Ardelyx appoints Ettenberg as Chief Legal Officer


Ardelyx appoints Rajani Dinavahi as chief medical officer

2026-04-01T12:17:42.000Z - 3 months ago

Ardelyx appoints Rajani Dinavahi as chief medical officer


Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Apr 1, 2026, 8:01 AM EDT - 3 months ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx


Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 4:20 PM EDT - 3 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026


Zevra Therapeutics appoints Renz as Chief Financial Officer

2026-03-05T13:09:46.000Z - 3 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA


Ardelyx to Participate in Upcoming Investor Conferences

Mar 4, 2026, 8:00 AM EST - 4 months ago

Ardelyx to Participate in Upcoming Investor Conferences


Ardelyx, LPGA announce multi-year partnership

2026-02-24T13:18:35.000Z - 4 months ago

Ardelyx, LPGA announce multi-year partnership


Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-20T11:12:08.000Z - 4 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright


Ardelyx reports Q4 EPS 0c, consensus 1c

2026-02-19T22:00:37.000Z - 4 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c


Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Ardelyx Earnings Call Transcript: Q4 2025


Ardelyx Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Ardelyx Earnings release: Q4 2025


Ardelyx Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Ardelyx Annual report: Q4 2025


Ardelyx Slides: Q4 2025

Feb 19, 2026, 4:30 PM EST - 4 months ago

Ardelyx Slides: Q4 2025


Ardelyx receives new patent for Tenapanor

2026-02-03T13:41:00.000Z - 5 months ago

Ardelyx receives new patent for Tenapanor


Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 5 months ago

Ardelyx Receives New Patent for Tenapanor


Ardelyx price target raised to $13 from $10 at TD Cowen

2026-01-29T14:35:34.000Z - 5 months ago

Ardelyx price target raised to $13 from $10 at TD Cowen


Ardelyx announces first patient dosed in ACCEL

2026-01-28T13:38:18.000Z - 5 months ago

Ardelyx announces first patient dosed in ACCEL


Ardelyx price target raised to $15 from $8 at Jefferies

2026-01-27T11:25:47.000Z - 5 months ago

Ardelyx price target raised to $15 from $8 at Jefferies


Ardelyx price target raised to $14 from $11 at Citi

2026-01-09T12:45:43.000Z - 5 months ago

Ardelyx price target raised to $14 from $11 at Citi


Ardelyx price target raised to $17 from $14 at BTIG

2026-01-09T11:00:13.000Z - 5 months ago

Ardelyx price target raised to $17 from $14 at BTIG


Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T21:35:56.000Z - 5 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler


Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T21:35:25.000Z - 5 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler


Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 11:30 AM EST - 7 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025


Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 10, 2025, 11:30 AM EST - 8 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference


Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Ardelyx Earnings Call Transcript: Q3 2025


Ardelyx Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Ardelyx Quarterly report: Q3 2025


Ardelyx Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Ardelyx Earnings release: Q3 2025


Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:35 AM EDT - 10 months ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025


Ardelyx Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 1:00 PM EDT - 10 months ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference


Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 11 months ago

Ardelyx Earnings Call Transcript: Q2 2025


Ardelyx Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 11 months ago

Ardelyx Quarterly report: Q2 2025


Ardelyx Earnings release: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 11 months ago

Ardelyx Earnings release: Q2 2025


Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 11 months ago

Ardelyx Announces Changes to the Executive Leadership Team


Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025


Ardelyx Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q1 2025


Ardelyx Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q1 2025


Ardelyx Slides: Corporate Presentation

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Ardelyx Slides: Corporate Presentation


Ardelyx Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Proxy statement: Proxy Filing


Ardelyx Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2025


Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia


Ardelyx Earnings Call Transcript: Q4 2024

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings Call Transcript: Q4 2024


Ardelyx Annual report: Q4 2024

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Annual report: Q4 2024


Ardelyx Earnings release: Q4 2024

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings release: Q4 2024


Noisy
Noisy Jun. 25 at 12:07 AM
$UNCY would be a good buyout target for $ARDX as a lower premium cost drug.
5 · Reply
ToadTrader
ToadTrader Jun. 24 at 6:23 PM
$ARDX Yep..... up to the "head bumping zone" ($6.35 to 6.44) then drop on down, retesting the area of test the 50% line of Monday's 24-hr range! Sideway Dancing..... on the 15-min chart I can see how the price checked back with the 200 SMA dipping down to the $5.75 level, the progressed up into the current working zone. Running now, in the same zone as we did back the last two weeks of May! As I study it all, you can seen then, that in Mid April we reached up to this same level, then tested back into the "BOX" ($5.65 Dip) then up to test higher ($7.47).... before then dipping through the BOX (lower side! $5.31) . This whole three month process is know as a RANGE EXPANSION, typically, an indication of accumulation by someone, be it Bears or Bulls....LOL Waiting it see the long term pattern.... working the daily runs to my preferred direction... study the progress in price to identify the the next wave.... catch the rising tides and avoid the undertows! Stay safe! CHEERS!
0 · Reply
opportoni
opportoni Jun. 24 at 6:19 PM
$ARDX Why all the complaining? After Q1 there were so many posts that this would bleed now with the long 3 months before we get q2 earnings and that we would reach $5 or worse by then. No catalysts and all that. Turns out, the SP holds up quite well. Even the warrant exercises with selling plans that caused drops in the past didn’t hurt. Neither did the proxy approvals. All is good. Time is on our side as it has (almost) always been with this one.
3 · Reply
VegasBlues
VegasBlues Jun. 24 at 6:12 PM
$ARDX $AQST All things considered… good day so far. 🍏🍻 One day hopefully 🤜🤛
0 · Reply
findingthestock
findingthestock Jun. 24 at 5:57 PM
$ARDX The stock price will not go anywhere until this CMS legal issue is resolved. It’s possible Q2 earning may happen before and will be better than Q1 how much better who knows and what will analysts think and the expenses Right now you can make more of a return with Wendy’s stock
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 24 at 5:34 PM
$ARDX v $AUPH valuation & revenue multiples. This is not investment advice & we're not here to bash AUPH. Lupkynis is an amazing drug & Tang just acquired 10% of AUPH. Our mere objective is to document the disconnect between ARDX's potential valuation assuming analyst revenue estimates are credible. ARDX product sales generated 97% gross margins in FY25 v 88% for AUPH. Analysts project ARDX to outsell AUPH by a factor of almost 2.5X over the next 5 years yet ARDX trades at a meaningfully lower valuation (even considering AUPH's $400MM net cash/debt). The attachment compares ARDX's valuation & related multiples v AUPH. We suspect eventually ARDX's BOD will do something so shareholder value is maximized (again assuming analyst revenue estimates are credible). $XBI $IBB $NBI
6 · Reply
Cap_00
Cap_00 Jun. 24 at 5:32 PM
$ARDX one of the least expensive commercial bios out there. Profitablity just around the corner. 1B by 2029 is achieved, Net revenue will be ~400m. Trading at 1.5B valuation. Peak sale for both I & X is around ~1.5-2B... patent to 2041. And they have a next gen NHE3 inhibitor that will announce IND by end of the year. Top notch CEO to boot. I think the lowest price target in in the $13 s. M&A chatter in the recent past. Stock has been getting bids lately. Perhaps, finally it's going break out from this long consolidation.
0 · Reply
Stocks2Retire
Stocks2Retire Jun. 24 at 5:03 PM
$ARDX finally money start flowing into biotechs- except this one, can they stop the cms nonsense and move forward once and for all!
0 · Reply
jbh973
jbh973 Jun. 24 at 4:27 PM
Many people here every day angrily ask why their particular ticker is down. Is it because of world economics? No. Perhaps a short attack? No. Could it possibly be do to a change in interest rates? Again, no. The simple & honest truth of it is that I most likely bought it. When u tick off God as many times as I have here & also in the afterlife, it's His easiest way to zap me. Perhaps I shouldn't of asked Him after my 2nd heart attack if all those fellas playing harps use pronouns he wouldn't of sent me back so quickly. Oh well. The never ending battle continues with THE MIDDAY STOCK MARKET REVIEW ( The I'm in no particular hurry so Heaven can wait Edition ) $NGEN Added more just because I'm a stubborn cuss. $CPB Pretty sure I single handedly knocked them off the S&P 500 but continue to add soup to my bowl. $LKNCY Adding despite China banning me from stepping foot on their soil. $ARDX Maybe something to do with Aardvarks? added more anyway. $NLY Raised divy. adding more with caution.
1 · Reply
VectorCapitall
VectorCapitall Jun. 24 at 3:45 PM
$ARDX continues to draw attention as investors focus on improving profitability and strong product growth. The company is approaching an earnings inflection point, while forward expectations continue to improve. Even under more conservative assumptions, the valuation remains compelling relative to future potential. The early August earnings report will be the next major catalyst.
0 · Reply
Paul_Volcker
Paul_Volcker Jun. 24 at 3:22 PM
$ARDX It appears that volume has been steadily increasing so far - let's hope that trend continues
0 · Reply
bams1017
bams1017 Jun. 24 at 3:04 PM
$ARDX Call crazy...just bought some Jan '27 $4 Calls for $2.70. Fingers crossed. Leaves room for Q4 business update in Jan which also includes Revenue and OpEx guidance for '27. Fingers crossed.
1 · Reply
Cameohitch
Cameohitch Jun. 24 at 12:36 PM
$ARDX This was uploaded today, but the player doesn't seem to be working: "Advancing Clinical Excellence Hyperphosphatemia Management in Dialysis-Dependent CKD" "Welcome to our premier learning center dedicated to advancing clinical excellence in hyperphosphatemia " Supported by an independent educational grant from Ardelyx https://www.medscape.org/advances/hyperphosphatemia-management-dialysis-dependent-ckd-2026a1000e25
0 · Reply
findingthestock
findingthestock Jun. 23 at 11:12 PM
$ARDX According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. How did this transaction impact Laura Williams's direct ownership stake? Williams's direct Common Stock holdings decreased by 17.8%, from 460,093 to 378,195 shares, reflecting a sizable but not total reduction of her position. https://www.fool.com/coverage/filings/2026/06/23/ardelyx-stock-up-70-what-to-know-about-this-usd490-000-insider-transaction/ This sale reduced Williams' stake, but her remaining ownership suggests continued alignment with shareholders. Strong revenue growth, expanding indications, and a healthy balance sheet remain the factors most likely to drive returns from here.
1 · Reply
UKbiotechInsider
UKbiotechInsider Jun. 23 at 8:34 PM
$ARDX that cross is inbound
2 · Reply
SpecialEdition
SpecialEdition Jun. 23 at 7:59 PM
$ARDX while other red stocks from my list fight to go green , this garbage is fighting to finish at lod …
2 · Reply
Lenni_D
Lenni_D Jun. 23 at 7:59 PM
$ARDX https://www.cureus.com/articles/493776-pharmacological-management-of-secondary-hyperparathyroidism-in-dialysis-patients-a-narrative-review-of-calcimimetics-vitamin-d-analogs-and-phosphate-binders#!/authors
0 · Reply
ToadTrader
ToadTrader Jun. 23 at 6:53 PM
$ARDX Yep... I see it.... Opened a few pennies below yesterday close.... climb to exceed the "head bumping zone" called out yesterday ($6.35 to 6.44) then drop on down to double test the 50% line of yesterday's 24-hr range! As it sits right now I thinking, (ya... I do that on occasion.... despite what my wife might be thinking!) Looking at the 15-min chart, the 200 SMA is slow walking uphill, likely to meet up with price action, tomorrow (Guessing $6.14, give or take a few pennies to turn the bus around!) Really, simply wanting to stay above $6.05 and stay out of the "BOX ZONE"...LOL Kicking out early today, to avoid paying more taxes! LOL Ya.... That's it.... Trade Safe.... Trade your Plan! CHEERS! You got to know.....
0 · Reply
bernardbaruch
bernardbaruch Jun. 23 at 6:49 PM
$ARDX “You need to break a few eggs in order to make an omelette” NIA
1 · Reply
bernardbaruch
bernardbaruch Jun. 23 at 6:02 PM
$ARDX indeed “haha” gushing about low. That’s my marker. I built a position both going into it and coming out of it. My basis is higher. However, I personally mark the beginning of the bull market in Ardelyx shares from 06/16/2022. Low trade that day was ~ $0.49 . SPY has doubled from its’ lows there. QQQ has tripled from its lows there. NVDA is up about 18 bags from its low around there. Ardelyx up 1160% How do you measure bull markets and bear markets? I use highs and lows. I’m also using supercycle on earnings for lack of a better description because I didn’t particularly trade the bull move to $10 nor the bear move to ~ $3.30. I’m here for the long ball. Multiple bags on relatively low basis driven by thesis supported earnings play. Price taker. Not a price maker. So far so good. Open to hearing from you a more appropriate level for marking the beginning of the bull market in Ardelyx vs 06/16/2022 ~$0.50 low from the $35 high post IPO.
0 · Reply
jbh973
jbh973 Jun. 23 at 3:32 PM
$ARDX For all I know ARDX is manufacturing mini-Sombreros for parakeets, but I see both @OldManLogan & @bernardbaruch are in this one then so am I.
2 · Reply
TonyStar
TonyStar Jun. 23 at 3:28 PM
$ARDX 2 opinions released today ,argued in December ,nothing for us
0 · Reply